600529 山东药玻
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)6.22110.70410.63113.24413.900
总资产报酬率 ROA (%)4.9478.5718.1399.82610.461
投入资产回报率 ROIC (%)5.6989.7189.36911.51111.806

边际利润分析
销售毛利率 (%)32.35128.03426.84429.61733.556
营业利润率 (%)22.55618.39316.98218.01919.762
息税前利润/营业总收入 (%)21.59017.56615.85917.73819.235
净利润/营业总收入 (%)18.37515.57114.76615.25316.470

收益指标分析
经营活动净收益/利润总额(%)100.719100.133104.360103.916106.650
价值变动净收益/利润总额(%)3.3504.5260.7701.8602.510
营业外收支净额/利润总额(%)-0.200-0.609-0.426-1.390-3.637

偿债能力分析
流动比率 (X)2.8743.2123.0171.9862.408
速动比率 (X)2.3542.6012.3311.4631.834
资产负债率 (%)21.72519.14720.74827.13724.292
带息债务/全部投入资本 (%)7.5517.7089.29613.347--
股东权益/带息债务 (%)1,213.2841,188.222967.571641.019859.655
股东权益/负债合计 (%)360.298422.288381.970268.499311.666
利息保障倍数 (X)-23.454-24.536-15.102-524.387115.667

营运能力分析
应收账款周转天数 (天)67.56866.54170.32865.2650.000
存货周转天数 (天)109.866113.684122.672107.3660.000